Skip to comments.Genes Show Limited Value in Predicting Diseases
Posted on 04/16/2009 10:37:59 PM PDT by neverdem
The era of personal genomic medicine may have to wait. The genetic analysis of common disease is turning out to be a lot more complex than expected.
Since the human genome was decoded in 2003, researchers have been developing a powerful method for comparing the genomes of patients and healthy people, with the hope of pinpointing the DNA changes responsible for common diseases.
This method, called a genomewide association study, has proved technically successful despite many skeptics initial doubts. But it has been disappointing in that the kind of genetic variation it detects has turned out to explain surprisingly little of the genetic links to most diseases.
A set of commentaries in this weeks issue of The New England Journal of Medicine appears to be the first public attempt by scientists to make sense of this puzzling result.
One issue of debate among researchers is whether, despite the prospect of diminishing returns, to continue with the genomewide studies, which cost many millions of dollars apiece, or switch to a new approach like decoding the entire genomes of individual patients.
The unexpected impasse also affects companies that offer personal genomic information and that had assumed they could inform customers of their genetic risk for common diseases, based on researchers discoveries.
These companies are probably not performing any useful service at present, said David B. Goldstein, a Duke University geneticist who wrote one of the commentaries appearing in the journal...
(Excerpt) Read more at nytimes.com ...
Common disease–common variant hypothesis: A theory that many common diseases are caused by common alleles that individually have little effect but in concert confer a high risk.
Complex disease: A disorder in which the cause is considered to be a combination of genetic effects and environmental influences.
Deep resequencing: A technique for sequencing a gene in several thousand subjects, typically with the use of high-throughput sequencing.
Epigenetics: The study of heritable changes to DNA structure that do not alter the underlying sequence; well-known examples are DNA methylation and histone modification.
Exome: All the expressed messenger RNA sequences in any tissue.
Fine mapping: The precise mapping of a locus after it has been identified by genetic linkage or association. The initial localization is determined within megabases of DNA in genetic linkage studies and within tens of kilobases in genetic association studies. In genetic association studies, fine mapping implies finding all the variants at the locus and trying to determine which changes may be related to pathogenesis with the use of statistical, functional, or bioinformatic methods.
Genes, Environment, and Health Initiative (GEI): A project funded by the National Institutes of Health to determine the relationships between genetic factors and disease. A proportion of the funding supports research of systematic ways to quantify environmental exposures.
Genetic association: A relationship that is defined by the nonrandom occurrence of a genetic marker with a trait, which suggests an association between the genetic marker (or a marker close to it) and disease pathogenesis.
Genetic linkage: A relationship that is defined by the coinheritance of a genetic marker with disease in a family with multiple disease-affected members.
Genomewide association study: A test of the association between markers, called single-nucleotide polymorphisms (SNPs), across the genome and disease, usually involving 300,000 or more markers that are reasonably polymorphic and are spread across the genome fairly evenly. This approach is hypothesis free (i.e., there is no existing hypothesis about a particular gene or locus but the null hypothesis that no detectable association exists).
Genotype-Tissue Expression (GTEx): A project funded by the National Institutes of Health that aims to study and map the relationship between human gene expression and genetic variation. The project, which is in a pilot phase, will analyze dense genotyping and expression data collected from multiple human tissues and will correlate genetic variation and gene expression, thus producing a list of genetic regions associated with expression of specific transcripts.
Haplotype: A series of polymorphisms that are close together in the genome. The distribution of alleles at each polymorphic site is nonrandom: the base at one position predicts with some accuracy the base at the adjacent position. Persons sharing a haplotype are related, often very distantly. Haplotypes in Europeans are generally of the order of tens of kilobases long; older populations, such as those of West Africa, tend to have shorter haplotypes, since a longer period of evolutionary time means more meiotic events and a greater chance of population admixture, both of which result in shorter haplotypes.
Haplotypic structure: The general underlying segmentation of the genome. As a result of recombination events occurring throughout the history of a population, contiguous segments of DNA are shared by persons within a population. Chromosomes can thus be broken down into contiguous segments, containing haplotypes common to members of particular populations.
HapMap: A catalogue of common genetic variation in humans compiled by an international partnership of scientists and funding agencies. Its goal was to determine the identity and length of haplotypes across the genome in different human populations. Stage 1 of the process, which was completed in 2005, yielded haplotype maps from SNPs present in at least 5% of chromosomes of each of three groups defined by ancestry: Yoruban, Northern and Western European, and Asian (Chinese and Japanese). Stage 2 involves determining haplotypes made up of SNPs with a lower prevalence (at least 1% of chromosomes) in these three groups and also in the Luhya and Maasai from Kenya, Toscani from Italy, Gujarati Indians, persons of Mexican ancestry, and persons of mixed African ancestry.
High-throughput sequencing: Several new techniques that since 2005 have increased the speed and decreased the cost of DNA sequencing by two orders of magnitude.
Human Genome Project: A coordinated international effort that led to the consensus sequence of the human genome.
Linkage disequilibrium: The nonrandom association of genetic markers; a set of markers in a haplotype are said to be in linkage disequilibrium.
Monogenic disease: A disorder caused by a mutation in a single gene (also called a mendelian disease).
Positional cloning: An approach for determining the position of a gene that, when mutated, causes monogenic disease. In families with disease, genetic markers from every chromosome are typed in both affected and unaffected members. Markers that are coinherited with disease indicate the chromosomal position of the genetic defect, and then genes at that position are sequenced to find the pathogenic mutation, which in turn indicates the causative gene.
Sequence motif: DNA sequences whose functions can be inferred because they are similar to sequences whose function has been biologically determined.
Structural genomic variation: Variation within the genome that results from deletion or duplication (both referred to as copy-number variation) or from inversion of genomic segments. Although common large variants (of more than one kilobase) exist, the majority of such variants are rare.
Transcriptome: A description of all DNA that is transcribed into RNA (messenger RNA, transfer RNA, microRNA, and other RNA species). The prevalence of a specific RNA sequence in a particular tissue may be proportionate to the relevance of that RNA species in the tissue.
1000 Genomes Project: A whole-genome resequencing of 1000 subjects from the original and extended HapMap populations, which was started in 2008, with funding from an international research consortium.
When I first read that viruses were capable of modifying DNA, I figured that the applicability of genome sequencing to illness prediction (see GATTACA movie) would be overrated. Nurture makes a comeback.
Thanks FrogMom.Other folks get fired for surfin' the web at work. A little later Venter was forced out as president of Celera.Scientist Reveals Genome Secret: It's HimWhen scientists at Celera Genomics announced two years ago that they had decoded the human genome, they said the genetic data came from anonymous donors and presented it as a universal human map. But the scientist who led the effort, Dr. J. Craig Venter, now says that the genome decoded was largely his own. Dr. Venter also says that he started taking fat-lowering drugs after analyzing his genes... [M]embers of Celera's scientific advisory board expressed disappointment that Dr. Venter subverted the anonymous selection process that they had approved... Though the five individuals who contributed to Celera's genome are marked by separate codes, Dr. Venter's is recognizable as the largest contribution. He said he had inherited from one parent the variant gene known as apoE4, which is associated with abnormal fat metabolism and the risk of Alzheimer's, and that he was taking fat-lowering drugs to counteract its effects... Dr. Arthur Caplan, a biomedical ethicist at the University of Pennsylvania, said, "Any genome intended to be a landmark should be kept anonymous. It should be a map of all us, not of one, and I am disappointed if it is linked to a person."
· Discover · Nat Geographic · Texas AM Anthro News · Yahoo Anthro & Archaeo · Google ·
· The Archaeology Channel · Excerpt, or Link only? · cgk's list of ping lists ·
Thanks for the ping!